Acurx Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

SHARE-BASED PAYMENTS TO VENDORS - Company Grants (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Oct. 31, 2019	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Granted		2,357,500
Share based compensation expense		$ 0	$ 175,000	$ 755,556	$ 508,333
Total compensation expense not yet recognized		$ 7,399,003		$ 7,399,003
Members' Equity, Class A
Granted	150,000	0	28,967	30,145	135,845
General and Administrative Expense
Share based compensation expense		$ 37,500	$ 37,500	$ 112,500	$ 112,500
Total compensation expense not yet recognized		$ 12,500		$ 12,500